Cancer

Cell culture and mouse studies suggesting inhibiting SET could help treat p53-mutant cancers. In a human p53-mutant bone cancer cell line, siRNA targeting SET decreased proliferation compared with scrambled siRNA. In a xenograft mouse model of p53-mutant colorectal cancer, shRNA targeting SET in the tumor decreased tumor growth compared with scrambled shRNA. Next steps could include testing SET inhibition in models of other p53-mutant cancer...